ALXN1007: Interim Phase IIa data

Interim data from 13 evaluable patients with newly diagnosed acute GvHD of the lower gastrointestinal tract in an open-label, U.S. and French Phase IIa trial showed that once-weekly 10 mg/kg ALXN1007 ...